PMID- 11849824
OWN - NLM
STAT- MEDLINE
DCOM- 20020411
LR  - 20190719
IS  - 0361-9230 (Print)
IS  - 0361-9230 (Linking)
VI  - 57
IP  - 2
DP  - 2002 Jan 15
TI  - Effects of selective cyclooxygenase enzyme inhibitors on 
      lipopolysaccharide-induced dual thermoregulatory changes in rats.
PG  - 179-85
AB  - The effects of selective cyclooxygenase-1 and cyclooxygenase-2 inhibitors 
      (valeryl salicylate and SC-58236, respectively) on Escherichia coli O111:B4 
      lipopolysaccharide (LPS)-induced dual thermoregulatory changes and serum tumor 
      necrosis factor-alpha elevation were investigated in rats. LPS (50 microg/kg, 
      intraperitoneal) produced an initial hypothermia that was then followed by fever. 
      Serum tumor necrosis factor-alpha levels elevated at the initial phase of 
      hypothermia. Valeryl salicylate injections (20, 40, and 80 mg/kg, subcutaneous 
      [s.c.]) completely inhibited hypothermia without any effect on the elevated serum 
      tumor necrosis factor-alpha levels and on the subsequent fever. On the other 
      hand, SC-58236 injections (10, 20, and 40 mg/kg, s.c.) only partially abolished 
      the hypothermia. SC-58236 had no effect on the initiation of fever, however 
      completely inhibited the maintenance of fever. The serum tumor necrosis 
      factor-alpha elevation was not reduced by SC-58236 treatment. The combination of 
      valeryl salicylate and SC-58236 also failed to inhibit the initiation of fever. 
      These findings suggest that cycloxygenase-1 may have a predominant role for the 
      development of LPS-induced hypothermia, but cyclooxygenase-1 does not seem to be 
      involved in the mediation of LPS-induced fever. Meanwhile, cyclooxgenase-2 may be 
      critical for the late phase rather than the initiation of the fever response in 
      rats.
FAU - Dogan, M Devrim
AU  - Dogan MD
AD  - Department of Pharmacology and Clinical Pharmacology, Faculty of Medicine, Ankara 
      University, Sihhiye 06100 Ankara, Turkey.
FAU - Ataoglu, Haluk
AU  - Ataoglu H
FAU - Akarsu, Eyup S
AU  - Akarsu ES
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Brain Res Bull
JT  - Brain research bulletin
JID - 7605818
RN  - 0 (4-(5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide)
RN  - 0 (Cyclooxygenase 2 Inhibitors)
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Cytokines)
RN  - 0 (Isoenzymes)
RN  - 0 (Lipopolysaccharides)
RN  - 0 (Membrane Proteins)
RN  - 0 (Prostaglandins)
RN  - 0 (Pyrazoles)
RN  - 0 (Salicylates)
RN  - 0 (Sulfonamides)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 0 (valerylsalicylate)
RN  - EC 1.14.99.1 (Cyclooxygenase 1)
RN  - EC 1.14.99.1 (Cyclooxygenase 2)
RN  - EC 1.14.99.1 (Prostaglandin-Endoperoxide Synthases)
RN  - EC 1.14.99.1 (Ptgs1 protein, rat)
SB  - IM
MH  - Animals
MH  - Body Temperature Regulation/*drug effects
MH  - Cyclooxygenase 1
MH  - Cyclooxygenase 2
MH  - Cyclooxygenase 2 Inhibitors
MH  - Cyclooxygenase Inhibitors/*pharmacology/toxicity
MH  - Cytokines/physiology
MH  - Fever/*chemically induced/prevention & control
MH  - Hypothermia/blood/*chemically induced
MH  - Isoenzymes/*drug effects
MH  - Lipopolysaccharides/*toxicity
MH  - Male
MH  - Membrane Proteins
MH  - Prostaglandin-Endoperoxide Synthases/*drug effects
MH  - Prostaglandins/physiology
MH  - *Pyrazoles
MH  - Rats
MH  - Rats, Wistar
MH  - Salicylates/*pharmacology/toxicity
MH  - *Sulfonamides
MH  - Tumor Necrosis Factor-alpha/*metabolism
EDAT- 2002/02/19 10:00
MHDA- 2002/04/12 10:01
CRDT- 2002/02/19 10:00
PHST- 2002/02/19 10:00 [pubmed]
PHST- 2002/04/12 10:01 [medline]
PHST- 2002/02/19 10:00 [entrez]
AID - S0361923001007390 [pii]
AID - 10.1016/s0361-9230(01)00739-0 [doi]
PST - ppublish
SO  - Brain Res Bull. 2002 Jan 15;57(2):179-85. doi: 10.1016/s0361-9230(01)00739-0.